NEUROCRINE BIOSCIENCES INC Debt Instrument, Face Amount
NEUROCRINE BIOSCIENCES INC (NBIX) had Debt Instrument, Face Amount of $170.40 million as of 2024-03-31, per its 10-Q filed 2024-05-01.
Discontinued › Notes › Debt
us-gaap:DebtInstrumentFaceAmount · last filed 2024-05-01
- 2024-03-31: Debt Instrument, Face Amount $170.40M.
- 2023-12-31: Debt Instrument, Face Amount $170.40M.
- 2021-12-31: Debt Instrument, Face Amount $381.20M.
- 2021-09-30: Debt Instrument, Face Amount $381.20M.
| Period end | Debt Instrument, Face Amount |
|---|---|
| 2024-03-31 | $170.40M 10-Q · filed 2024-05-01 |
| 2023-12-31 | $170.40M 10-Q · filed 2024-05-01 |
| 2021-12-31 | $381.20M 10-K · filed 2022-02-11 |
| 2021-09-30 | $381.20M 10-Q · filed 2021-11-01 |
| 2021-06-30 | $381.20M 10-Q · filed 2021-08-03 |
| 2021-03-31 | $381.20M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $381.30M 10-K · filed 2022-02-11 |
| 2020-09-30 | $517.50M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $517.50M 10-Q · filed 2020-08-03 |
| 2020-03-31 | $517.50M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $517.50M 10-K · filed 2021-02-05 |
| 2019-09-30 | $517.50M 10-Q · filed 2019-11-04 |
| 2019-06-30 | $517.50M 10-Q · filed 2019-07-29 |
| 2019-03-31 | $517.50M 10-Q · filed 2019-04-29 |
| 2018-12-31 | $517.50M 10-K · filed 2020-02-07 |
| 2018-09-30 | $517.50M 10-Q · filed 2018-11-05 |
| 2018-06-30 | $517.50M 10-Q · filed 2018-07-31 |
| 2018-03-31 | $517.50M 10-Q · filed 2018-04-30 |
| 2017-12-31 | $517.50M 10-K · filed 2019-02-08 |
| 2017-09-30 | $517.50M 10-Q · filed 2017-11-01 |
| 2017-06-30 | $517.50M 10-Q · filed 2017-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |